This Waltham firm's gonorrhea drug could prevent a global health 'nightmare'

Thanks to a new partnership deal, Waltham-based Entasis Therapeutics said Thursday that it plans to advance its lead antibiotic — a treatment for drug-resistant gonorrhea — into a pivotal Phase 3 trial next year. Privately-held Entasis said the trial will be funded by a nonprofit called the Global Antibiotic Research and Development Partnership, or GARDP, a joint initiative launched last year by the World Health Organization and the Drugs for Neglected Diseases Initiative. A representative for…